The Impact of Androgenetic Alopecia and Its Treatment Protocols on the Sexual Life of Affected Males and Females: An Analytical Literature Review

Iman Mohamed Elwan Elmeaday *

Mediclinic al Mussafah, Abu Dhabi, UAE.

*Author to whom correspondence should be addressed.


Abstract

Out of the several cosmetic-related problems that both men and women face during their lifetime, hair loss is one of the most common ones. There are several causes behind hair loss, but the most common ones are seen to sprout from a variety of genetic and environmental reasons. Almost a wide majority of the cases of hair loss are hereditary and run in families. Androgenetic Alopecia is one of the most common types of hair loss that both men and women experience. Although it is not necessary for androgenetic alopecia to affect one gender more than the other, it is normally seen that people of either gender who have had a significant family history of experiencing more hair fall, would ultimately be more predisposed to develop it at a particular time in their life. Although it seems to be an irreversible and never-ending issue, there have been several treatments prescribed that help reverse and resolve the problem, while giving rise to new hair growth as well. However, the treatments might have side effects of their own. This review deals with the sexual side effects or problems that might arise as a consequence of taking treatment for Androgenetic Alopecia. Loss of libido, erectile dysfunction, decreased interest, and gynecomastia are some of the common side effects that are linked with the various treatment protocols that have been prescribed for Androgenetic Alopecia. This review will explore these side effects and the mechanisms that cause these problems to arise in the first place.

Keywords: Androgenetic alopecia, hair loss, genetic, sexual dysfunction, loss of libido


How to Cite

Elmeaday , I. M. E. (2023). The Impact of Androgenetic Alopecia and Its Treatment Protocols on the Sexual Life of Affected Males and Females: An Analytical Literature Review. Asian Journal of Research in Dermatological Science, 6(1), 68–74. Retrieved from https://journalajrdes.com/index.php/AJRDES/article/view/88

Downloads

Download data is not yet available.

References

Phillips TG, Slomiany WP, Allison R. Hair Loss: Common Causes and Treatment. Am Fam Physician. 2017;15;96(6):371–8.

Al Aboud AM, Zito PM. Alopecia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Accesson. 2023;10.

Available:http://www.ncbi.nlm.nih.gov/books/NBK538178/

Ho CH, Sood T, Zito PM. Androgenetic Alopecia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Accesson. 2023;9. Available:http://www.ncbi.nlm.nih.gov/books/NBK430924/

Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, et al. Androgenetic alopecia: A review. Endocrine. 2017;57(1): 9–17.

Mahmoudi H, Salehi M, Moghadas S, Ghandi N, Teimourpour A, Daneshpazhooh M. Dermoscopic Findings in 126 Patients with Alopecia Areata: A Cross-Sectional Study. Int J Trichology. 2018;10(3):118–23.

Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic Alopecia: Therapy Update. Drugs. 2023;83(8):701-15.

Dharam Kumar KC, Kishan Kumar YH, Neladimmanahally V. Association of Androgenetic Alopecia with Metabolic Syndrome: A Case–control Study on 100 Patients in a Tertiary Care Hospital in South India. Indian J Endocrinol Metab. 2018;22(2):196–9.

Tanaka Y, Aso T, Ono J, Hosoi R, Kaneko T. Androgenetic Alopecia Treatment in Asian Men. J Clin Aesthetic Dermatol. 2018;11(7):32–5.

Asfour L, Cranwell W, Sinclair R. Male Androgenetic Alopecia. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Accesson. 2023;10.

Available:http://www.ncbi.nlm.nih.gov/books/NBK278957/

Krupa Shankar D, Chakravarthi M, Shilpakar R. Male Androgenetic Alopecia: Population-Based Study in 1,005 Subjects. Int J Trichology. 2009;1(2):131–3.

Piraccini BM, Alessandrini A. Androgenetic alopecia. G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr. 2014 Feb;149(1):15–24.

Murphrey MB, Agarwal S, Zito PM. Anatomy, Hair. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Accesson. 2023;10. Available:http://www.ncbi.nlm.nih.gov/books/NBK513312/

Marks LS. 5α-Reductase: History and Clinical Importance. Rev Urol. 2004;6 (Suppl 9):S11–21.

Li SJ, Huang KP, Joyce C, Mostaghimi A. The Impact of Alopecia Areata on Sexual Quality of Life. Int J Trichology. 2018;10(6): 271–4.

Natarelli N, Gahoonia N, Sivamani RK. Integrative and Mechanistic Approach to the Hair Growth Cycle and Hair Loss. J Clin Med. 2023;23;12(3):893.

Singh S, Muthuvel K. Practical Approach to Hair Loss Diagnosis. Indian J Plast Surg Off Publ Assoc Plast Surg India. 2021;27;54(4):399–403.

Rossi A, Anzalone A, Fortuna MC, Caro G, Garelli V, Pranteda G, et al. Multi-therapies in androgenetic alopecia: review and clinical experiences. Dermatol Ther. 2016;29(6):424–32.

Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;9;13:2777–86.

Badri T, Nessel TA, Kumar DD. Minoxidil. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Accesson 2023;10. Available:http://www.ncbi.nlm.nih.gov/books/NBK482378/

Salisbury BH, Tadi P. 5-Alpha-Reductase Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2023. Accesson 2023;10.

Available:http://www.ncbi.nlm.nih.gov/books/NBK555930/

Zito PM, Bistas KG, Syed K. Finasteride. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

Accesson 2023;10. Available:http://www.ncbi.nlm.nih.gov/books/NBK513329/

Wang C, Du Y, Bi L, Lin X, Zhao M, Fan W. The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review. Clin Cosmet Investig Dermatol. 2023;9; 16:603–12.

Rozner RN, Freites-Martinez A, Shapiro J, Geer EB, Goldfarb S, Lacouture M. Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. Breast Cancer Res Treat. 2019;174(1):15–26.

Pillai JK, Mysore V. Role of Low-Level Light Therapy (LLLT) in Androgenetic Alopecia. J Cutan Aesthetic Surg. 2021;14(4):385–91.

Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021;20(12):3759–81.

Sancak EB, Oguz S, Akbulut T, Uludag A, Akbas A, Kurt O, et al. Female sexual dysfunction in androgenetic alopecia: Case-control study. Can Urol Assoc J. 2016;10(7–8):E251–6.

Coskuner ER, Ozkan B, Culha MG. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors. Sex Med Rev. 2019;7(2):277– 82.

Hagberg KW, Divan HA, Fang SC, Nickel JC, Jick SS. Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin Epidemiol. 2017;9:83–91.

Gordon KA, Tosti A. Alopecia: Evaluation and treatment. Clin Cosmet Investig Dermatol. 2011;4:101–6.

Vidal CI. Overview of Alopecia: A Dermatopathologist’s Perspective. Mo Med. 2015;112(4):308–12.